Analyzing...
Loading company...
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,198 Cr revenue.
COGS 25.5%, employees 20.8%.
“Our vision of $1,000,000,000 business by 2030 remains there. We are committed to reach there”
“we remain committed to really go on that journey [to $1 billion vision] as fast as we can and as steady as we can”
“This new structure is designed to bring greater agility, faster execution and deeper accountability across our businesses...positions Hohen strongly on its path towards a $1,000,000,000”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 5.3%▼ | 10.5% |
| ROCE | 5.5%▼ | 13.8% |
| Net Margin | 9.6%▲ | 8.7% |
| EBITDA Margin | 20.8%▲ | 16.0% |
| Debt To Equity | 0.06x▼ | 0.21x |
| Rev Growth 3yr | -3.8%▼ | 5.8% |
| EPS Growth 3yr | -16.1%▼ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹2,051 Cr +71.3% | ₹1,198 Cr +13.9% | ₹1,051 Cr -21.6% | ₹1,340 Cr +1.5% | ₹1,320 Cr +30.8% | ₹1,010 Cr +21.1% | ₹834 Cr |
| Other Income | ₹47 Cr -20.6% | ₹59 Cr -5.4% | ₹62 Cr +33.5% | ₹46 Cr -49.8% | ₹92 Cr +548.9% | ₹14 Cr -21.4% | ₹18 Cr |
| Total Income | ₹2,098 Cr +67.0% | ₹1,256 Cr +12.8% | ₹1,113 Cr -19.7% | ₹1,387 Cr -1.8% | ₹1,413 Cr +38.0% | ₹1,024 Cr +20.2% | ₹852 Cr |
| COGS | ₹582 Cr +90.7% | ₹305 Cr -3.1% | ₹315 Cr -23.0% | ₹409 Cr +2.5% | ₹399 Cr +32.2% | ₹302 Cr +31.7% | ₹229 Cr |
| ₹1,846 Cr +102.4% | ₹912 Cr +28.9% | ₹708 Cr -14.4% | ₹827 Cr +5.2% | ₹786 Cr +28.9% | ₹610 Cr +23.1% | ₹496 Cr | |
| Profit Before Tax | ₹239 Cr -30.6% | ₹344 Cr -15.2% | ₹406 Cr -27.5% | ₹560 Cr -10.7% | ₹626 Cr +51.3% | ₹414 Cr +16.2% | ₹356 Cr |
| Exceptional Items | (₹13 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹58 Cr -26.5% | ₹79 Cr -24.9% | ₹105 Cr -29.0% | ₹148 Cr -30.6% | ₹214 Cr +103.0% | ₹105 Cr +20.4% | ₹88 Cr | |
| Net Profit | ₹181 Cr -31.8% | ₹265 Cr -11.8% | ₹300 Cr -27.0% | ₹411 Cr -9.4% | ₹454 Cr +25.2% | ₹362 Cr +14.3% | ₹317 Cr |
| Profit (Owners) | ₹202 Cr -24.7% | ₹268 Cr -10.8% | ₹300 Cr -27.0% | ₹411 Cr -9.4% | ₹454 Cr +25.2% | ₹362 Cr +14.3% | ₹317 Cr |
| Minority Interest | (₹21 Cr) -582.3% | (₹3 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | ₹23 Cr +73.8% | ₹13 Cr -0.5% | ₹13 Cr ↑ Recovery | (₹0.19 Cr) +75.6% | (₹0.76 Cr) +8.9% | (₹0.84 Cr) -2.3% | (₹0.82 Cr) |
| EPS | ₹5.83 | ₹10.52 | ₹11.80 | ₹16.16 | ₹17.83 | ₹14.23 | ₹12.45 |
| Diluted Shares | ₹38 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Cohance Lifesciences Limited has informed the Exchange about Schedule of meet
Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Cohance Lifesciences Limited has informed the Exchange about Schedule of meet
Significant movement in price has been observed in Cohance Lifesciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the ma...
Cohance Lifesciences Limited has informed the Exchange about Brief profile of Mr. Umang Vohra, Chairman and Group CEO
Cohance Lifesciences Limited has informed the Exchange regarding a press release dated April 27, 2026, titled "Press Release".
Cohance Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on April 27, 2026.
Cohance Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Cohance Lifesciences Limited has informed the Exchange about Schedule of meet
Cohance Lifesciences Limited has informed the Exchange about Transcript
Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Cohance Lifesciences Limited has informed the Exchange about Link of Recording
Cohance Lifesciences Limited has informed the Exchange about Investor Presentation
Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
Cohance Lifesciences Limited has informed the Exchange about additional information on USFDA announcement